Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

© 2014 The Royal Society of Chemistry. α-Synuclein (α-Syn), a protein synthesized by neurons, as the major protein component of Lewy body inclusions, undoubtedly has a prominent role in the pathogenesis of Parkinson's Disease (PD). In an attempt to enable pre-symptomatic and definitive diagnosis, numerous attempts have been made to align assayed total α-Syn levels in serum (where there is a native presence) to PD disease status. Results have been conflicting. The status of circulating and potentially neuroprotective α-Syn autoantibodies in PD subjects is also unclear. In previous work we demonstrated that electrochemically assayed autoantibody levels were higher in PD patients compared to controls and, significantly, noted that this differentiation was most marked early in disease. Herein we report a robust (coefficient of variation 3.0%) single step and label free analysis of 90 subjects, including 60 PD patients, with a mean disease duration of 1.4 years and 29 control subjects. In this cross sectional cohort we observe a statistically significant (p < 0.05; Mann-Whitney U test) difference in autoantibody levels in PD patients versus controls, although there was no resolved scaling with symptomatic disease stage (p > 0.05; Kruskal-Wallis test).

Original publication




Journal article


RSC Advances

Publication Date





58773 - 58777